8IOU image
Entry Detail
PDB ID:
8IOU
EMDB ID:
Title:
Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Biological Source:
PDB Version:
Deposition Date:
2023-03-13
Release Date:
2023-05-24
Method Details:
Experimental Method:
Resolution:
3.18 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Mutations:F817P, A892P, A899P, A942P, K986P, V987P, R682G, R683S, R685G
Chain IDs:A, B, C
Chain Length:1245
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:Processed angiotensin-converting enzyme 2
Chain IDs:D
Chain Length:608
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures